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Abbreviations 
ACS  - Acute coronary syndromes 
ADP  - Adenosine diphospate receptor 
AMI  - Acute myocardial infarction 
CABG  - Coronary artery bypass graft surgery 
CAD  - Coronary artery disease 
CI  - Confidence interval 
CIE  - Composite endpoint of the reported ischemic events 
CV  - Cardiovascular death 
HPR  - High on-clopidogrel platelet reactivity 
HR  - Hazard ratio 
IABP  - Intraaortic balloon pump 
IPA  - Post-treatment platelet reactivity 
LTAADP  - ADP-stimulated light transmission aggregometry 
MACCE - Major adverse cardiac and cerebrovascular events 
MACE  - Major adverse cardiovascular events 
MD  - Mean difference 
MEAADP - Multiple electrode aggregometry with ADP stimuli 
MI  - Myocardial infarction 
NOS  - Newcastle-Ottawa Scale 
OPCAB - Off pump coronary artery bypass 
OR  - Odds ratio 
POBA  - Percutaneous balloon angioplasty 
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PCI  - Percutaneous coronary intervention 
RBC  - Red blood cell transfusion 
ROC  - Receiver-operating characteristic 
ST  - Stent thrombosis 
STEMI  - ST segment elevation myocardial infarction 
TFPCI  - Transfemoral coronary intervention 
TRPCI  - Transradial coronary intervention 
TVR  - Target vessel revascularization 
TXA  - Tranexamic acid 
UFH  - Unfractionated heparin 
VASP  - Flow cytometric assessment of vasodilator-stimulated 
phosphoprotein phosphorylation assay 
  
6 
 
1 Introduction 
1.1 Short history 
Meta-analysis is a statistical technique for summarising, and reviewing previously published 
quantitative research. Practioners, clinicians have to face an informational boom of the 
modern medicine. There is too much information around for people to keep up to date, on 
the other hand high quality information is often not easy to find. Elaborating a summary of 
available literature and performing a critical review of the obtained data is becoming more 
and more important. Using meta-analysis, a specially developed statistical armamentarium 
that allows cumulating the available data of independent observation, enables to analyse a 
wide variety of questions and allows not only a summary but also an integration of the 
evidences with higher statistical power and more precise effect estimates.  
The first meta-analysis was performed by Karl Pearson in 1904, who analyzed the data from 
five studies on the correlation between the vaccination for enteric fever and its mortality. (1) 
He observed separate sets of data from different geographical locations. It is an early 
example of meta-analysis, and yet it has all the features of a correct meta-analysis. The first 
written work on the methodology of combining the results of different studies was given by 
Tippett in 1931, and then shortly by Pearson in 1933, who independently proposed a 
method for combining tests of statistical significance based on the product of the P values 
across studies. (2; 3) Also, Cochran in 1937 and Yates and Cochran in 1938 in their early work 
combined information across experiments in the agricultural sciences in order to derive 
estimates of treatment effects and test their significance. (4; 5) See also Mosteller and Bush in 
1954, Glass, McGaw and Smith in 1981, then Hunter, Schmidt and Jackson in 1982, Hedges 
and Olkin in 1985 and Cooper and Hedges in 1994 for further investigation on the history of 
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meta-analysis that is widely used in epidemiology and evidence-based medicine today. (6; 7; 8; 
9; 10) 
1.2 Background 
Coronary artery disease (CAD) is the predominant cause of heart disease and the leading 
cause of death worldwide. In recent decades new treatments have been developed in for its 
management. Coronary-artery bypass grafting (CABG), introduced in 1968, was the only 
method of coronary revascularization until 1977, when percutaneous balloon angioplasty 
(POBA) was first performed by Andreas Grüntzig, which was seen as an innovative non-
surgical alternative to CABG. (11; 12) Since their inception, both techniques have undergone 
evolutions that have reduced rates of morbidity and mortality despite the increasing age and 
prevalence of co-morbidities in the patient population receiving revascularization. In the 
1990s, the introduction of stents led to reduced rates of complications of POBA. Stent 
implantation dramatically improved the overall success rate of percutaneous coronary 
intervention (PCI), but some short and longer term complication has been realized. In 
patients after PCI, the antiplatelet therapy has radically reduced the rate of ischemic events. 
As acute coronary syndrome seems to be associated with a need for higher degree inhibition 
of platelet activation the current trends involve the use of more potent antiplatelets as well 
as intensified antiplatelet and anticoagulation protocols. Yet, despite these efforts acute 
stent thrombosis still occurs that suggest that optimal antiplatelet effect is still not achieved 
in a proportion of patients, while use of more aggressive regimes may encounter a higher 
risk for periprocedural bleeding complications. Nevertheless there is an important inter-
individual difference in response to antiplatelet therapy. These differences seem to be 
significant in terms of the prognosis of the patient but heterogeneity in the methodology still 
hampers the wide-spread clinical use of these tests. 
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1.3 Methodical aspects of meta-analysis: selection of studies, quality 
assessment 
1.3.1 Planning a meta-analysis 
Systematic reviews aim to find and assess with statistical and analytical methods for 
inclusion all high quality studies addressing a question and integrate the study results into a 
common result. Performing a meta-analysis can be simplified to four essential stages. The 
first step is to define the question with excluding and including criteria for the research 
studies. The second is to perform a systematic search for literature in order to capture all 
available studies addressing the question in the medical literature. Currently keyword 
dependent search of electronic databases such as Pub Med, the Web of Science®, and the 
Cochrane Central Register of Controlled trials is used for this aim. The third step is 
calculation with mathematical and statistical formulas results for each study and combine 
them. Final step is the interpretation of the results of meta-analysis and give an answer and 
conclusion to the question. 
1.3.2 Quality assessment 
The quality of the included studies is important as it may influence the overall credibility of 
the meta-analysis. The inclusion criteria themselves already include some key features 
defining the minimal required information that qualify a report for inclusion. Randomized 
studies generally performed in high quality that makes their interpretation easy, however 
the restrictions of the involved group of patient sometimes impairs the generalization of 
their findings. The observational studies are less standardized consequently more 
heterogeneous in quality; however they reflect the praxis of the real-world circumstances. 
Quality assessment may also provide information about why the results of some included 
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studies differ from others. Similarly it is important to assess, as to whether an effect can be 
verified in the whole spectrum of studies or it is influenced by the application environment.  
To estimate study quality scoring systems are used. Generally accepted scoring system for 
non-randomized studies; is the Newcastle-Ottawa Scale (NOS). The scale allocate stars, 
maximum of nine, for the presence of the following: 1) representativeness and 2) selection 
of the study, 3) ascertainment of intervention, 4) demonstration of outcome, 5) 
comparability (max: 2 stars), 6) assessment of outcome, 7) duration of follow-up, 8) 
adequacy of follow-up. An another method, which can allocate the quality of study is the 
less well standardized, however more detailed score, modified from Jadad et al. and Biondi-
Zoccai et al. (13; 14; 15) In this scale quality is expressed on an ordinal scale, allocating 1 point 
for the presence of each of the following: 1) statement of objectives; 2) explicit inclusion and 
exclusion criteria; 3) description of interventions; 4) objective means of follow-up; 5) 
description of adverse events; 6) power analysis; 7) description of statistical methods; 8) 
multicenter design; 9) discussion of withdrawals; and 10) details of medical therapy. 
1.3.3 Data structure 
Data reported by the included studies may be given in different forms. This influences the 
statistical model selection. When the studies have a dichotomous, binary outcome the 
results of each study can be presented in a 2×2 table (Table 1) giving the numbers of 
participant who has or not the event in each of the two groups. 
1. Table: Binary data 
Study i Event No event Total 
Experimental ai bi n1i 
Control ci di n2i 
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If the reported outcome is a continuous variable, the number of patients in each of the two 
groups, their mean response and the standard deviation of their responses are required to 
perform meta-analysis (Table 2). 
2. Table: Continuous data  
Study i Group size 
Mean 
response 
Standard 
deviation 
Experimental n1i m1i sd1i 
Control n2i m2i sd2i 
 
There is a generic approach, for other outcomes. When study report odds or hazard ratios, 
after calculation it can be expressed on a log-scale with standard error, which calculable 
from the confidence interval. The involved patient’s number can optionally be entered by 
the author, but are not included in the analysis. (16) (Table 3) 
3. Table: Generic data 
Study i 
Estimate of 
effect 
Standard error 
of estimate 
Group size 
(experimental) 
Group size 
(control) 
   n1i n2i 
 
1.3.4 Endpoints 
The endpoints of interest are typically continuous and categorical variable. A continuous 
variable define one points on a line and has numeric or quantitative value, which can 
measure length, weight or time. The categorical variable is not quantitative and has no 
numerical meaning. It takes a value that is one of several possible categories, like hair color 
or gender. In several studies the reported event frequencies are categorical variables. These 
are mortality, red blood cells transfusion, reoperation, cardiovascular death, 
definite/probable stent thrombosis and non-fatal myocardial infarction. In some cases 
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driven by their common pathological background or their common influence on the patients 
outcome composite endpoint are created. An example for the former is the major adverse 
cardiologic events (MACE) or the major adverse cardiac and cerebrovascular events 
(MACCE). These measures are of widespread use in cardiologic clinical research as hard 
clinical endpoint. Here cardiac mortality, myocardial infarction and cerebrovascular events 
are composed together based on their similar background as different manifestation of the 
atherosclerotic coronary disease. In studies where clinical outcome of patient after coronary 
interventions are followed-up the MACE is frequently amended with the number of target 
vessel revascularization (TVR). Recent understanding on the timing of stent thrombosis 
resulted in a classification that defines definite, probable and possible stent thrombosis 
emphasizing that some event may happen clinically unnoticed. (17) In recent studies 
supported by the data on relevance of bleeding events efficacy endpoints (like MACE) and 
safety endpoints (like bleeding) reported as a composite endpoint of net clinical outcome. (18) 
It is a frequently encountered problem that different studies use different endpoint criteria 
for the same event. An example of this is the bleeding where wide variety of bleeding 
criteria are available that incorporates treatment (amount of red blood cell transfusion or 
the surgical haemostasis required), laboratory (decrease of blood hemoglobin or hematocrit 
with a given level) or clinical (like in case of intracranial bleeding) characteristics. To 
overcome such heterogeneity review of literature can use so called consensus endpoint and 
subgroup analyses can be performed to ascertain as to whether the studies reporting and 
reporting not consensus endpoint share similar characteristics. 
1.3.5 Statistical models 
Meta-analysis is the use of statistical methods to combine results of individual studies. This 
allows making the best use of all the information. The difficulty is to integrate all those 
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different studies into one study. The effect size, which can be odds ratio, risk ratio, 
correlation coefficient, mean difference, standard mean difference is the most important 
value in meta-analysis. After standardization it can be comparable across studies. The 
number of patients varies from study to study; therefore the effect size is depending on 
sample size. In the analysis it can bypass with giving “weight”, which dependent on 
deviation, to each study.  The weight of each study is given by the inverse of the variance: 
 
where Wi is the weight and Vi the variance of the outcome of the study. Variance defines the 
imprecision of the reported data, therefore if V is small, W will converge to 1, to 100% and 
the study will have greater weight in the final result of the analysis. 
There are two statistical approaches the fixed and random effect model. Fixed effect model 
is based on a mathematical hypothesis that each study is evaluating a common treatment 
effect. That means the effect of treatment, allowing for the play of chance, was the same in 
all studies. Conversely the random effect model is an alternative approach that does not 
assume that a common or fixed treatment effect exists. This model assumes that the true 
treatment effects in the individual studies may be different from each other and may be 
influenced by chance. In studies of human population medical reports usually the more 
robust random effect can preferably used. Similarly, if statistical heterogeneity is high 
between the studies in the review, the random effects model may be better choice. (16) 
The Mantel-Haenszel approach was developed by Mantel and Haenszel in 1959. (19) This 
method assumes a fixed effect and gives the weight of the investigated study with inverse 
variance approach. The Mantel-Haenszel pooled odds ratio is given by: 
13 
 
 
The alternative for calculation of the logarithmic (log) odds ratio, mean difference or 
standardized mean difference is the DerSimonian and Laird random-effects model that is 
given by (10): 
 
The estimate of τ2 is given by: 
 
where the Wi are the inverse-variance weights. 
A specialized case of the random effect model is the inverse-variance method that is 
appropriate to pool log ORs of observational studies. The intervention effect estimate is 
denoted by I and the investigated studies are weighted according to the reciprocal of their 
variance: 
. 
These are combined to give a pooled estimate 
, 
with 
. 
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1.3.6 Test for heterogeneity 
Beside the direction, magnitude and confidence intervals of an effect estimate it is an 
important aspect how far the available data are heterogeneous in this aspect, and thus a 
conclusion how far can be generalized. The heterogeneity can be calculated with use of the 
following formulas: 
 
where  represents the log odds ratio, log risk ratio or risk difference and the Wi are the 
weights. The statistic I2 is calculated as:  
 
where k is the number of studies contributing to the meta-analysis. 
1.3.7 Subgroup analyses 
Heterogeneity of the treatment effect can be resolved with subgroup analysis. Subgroup 
analyses have altogether weaker statistical power as they have less case included. Thus 
subgroup analysis can unveil that the effect can or cannot be reproduced in certain studies, 
and on the other hand when subgroup analyses reveal the same characteristics in wide 
range of studies can underline the robustness of the data. 
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2 Relations of clinical outcomes, bleeding risk and antiplatelet 
therapy after coronary revascularizations 
2.1 Transradial versus femoral percutaneous coronary intervention in 
acute myocardial infarction 
Transradial coronary angioplasty (TRPCI) has gained widespread acceptance since its 
introduction by Kiemeneij and Laarman. (20) Radial access has been proven to be a highly safe 
and effective technique for both diagnostic- and therapeutic procedures. (13; 21) Advantages 
of the transradial approach over the transfemoral include safe and easy haemostasis due to 
compressibility of the artery, and consequent lack of need for post procedural bed rest 
permitting immediate ambulation, greater comfort, and earlier discharge. These have been 
shown to reduce the costs of hospitalization and improve quality of life for patients. (22; 23) 
Although it is technically more challenging, transradial intervention is feasible in the setting 
of acute coronary syndromes. (24; 25; 26; 27; 28; 29; 30) The major advantage of the TRPCI is the 
near elimination of clinically significant access site complications, even in patients at high 
risk (i.e. patients treated with GP IIb/IIIa inhibitors or shortly after systemic thrombolysis). 
Bleeding events, and the consequent need for transfusion, are independent determinants of 
survival in acute coronary syndromes. Their relation to short- and long-term mortality has 
been demonstrated in major randomized trials as well as through the evaluation of 
registries. (31; 32; 33; 34) Low incidence of vascular access site bleeding complications suggests 
that the transradial approach may be a safe alternative to the femoral technique employed 
in acute myocardial infarction with ST segment elevation (STEMI), particularly when an 
aggressive anticoagulation- and antiplatelet regimen is applied. On the contrary, the possible 
greater occurrence of procedural failure and longer procedural times occasioned by difficulty 
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in puncturing the radial artery, inability to cannulate the coronaries, or impossibility to 
perform the angioplasty, are factors that raise concerns as to whether radial access remains 
beneficial in the setting where timely reperfusion is critical, in STEMI for instance. The safety 
of transradial- and transfemoral PCI in AMI were compared in numerous trials; however, 
most of them included small patient groups. Despite consistent demonstration of lower 
bleeding rates, only inconclusive results are available regarding recurrent ischemic events; 
most of these studies were underpowered to evaluate this issue. 
2.2 Outcome in patients undergoing cardiac surgery after preoperative 
treatment with clopidogrel 
Large body of evidence supports the application of dual antiplatelet therapy (DAPT) in 
patients with acute coronary syndromes (ACS) and after percutaneous coronary 
interventions. (35; 36; 37; 38; 39) Clopidogrel, an irreversible inhibitor of the platelet P2Y12 ADP-
receptor, is the cornerstone of the DAPT. The inhibitory effect of clopidogrel lasts for the 
whole life-span of the platelet as platelets are not capable for protein synthesis. Due to the 
slow onset of action, clopidogrel is recommended in an oral bolus before coronary 
angiography to achieve rapid platelet inhibition in patients with ACS. (40; 41) In the past years, 
aggressive clopidogrel based antiplatelet protocols have been shown to be effective in 
reducing recurrent thrombo-ischemic events. (42; 43; 41; 44) This strategy is predominantly 
important in patients with ACS, in whom the prompt and potent antiplatelet therapy is 
associated with the greatest clinical benefit. Although most patients with ACS are candidates 
for percutaneous coronary interventions (PCI), some patients with ACS require surgical 
revascularization. This proportion is low among those with ST-segment elevation myocardial 
infarction (MI), but can reach 10% in patients with non-ST segment elevation MI. (45) 
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Similarly, there are also many stable angina patients taking clopidogrel before coronary 
artery bypass grafting (CABG) procedures due to the prior PCI or acute coronary event. As a 
result, the administration of clopidogrel is quite common before cardiac surgery. (46) As the 
impaired platelet function during CABG might be associated with higher rate of bleeding 
complications, it is recommended to discontinue clopidogrel for at least five days before 
surgery. (45) However, in certain cases, it is not possible to wait for the wash-out period, and 
many patients undergo surgical revascularization under the effect of clopidogrel. On the 
other hand some recent studies support that persisting inhibition of platelet aggregation 
beside the higher risk for bleeding may have beneficial effect in terms of reduction of 
perioperative myocardial infarction or graft patency. (34; 47; 48) 
Several studies intended to clarify the potential harm and benefit associated with 
clopidogrel therapy prior to CABG. As these studies resulted in heterogeneous and 
inconclusive results currently, there is no consensus regarding the impact of clopidogrel 
treatment on clinical outcome after cardiac surgery. (49) Our main goal was to perform a 
systematic review of the literature to evaluate the impact of clopidogrel treatment on 
clinical outcomes in patients undergoing cardiac surgery. 
2.3 Prognostic significance of high on-clopidogrel platelet reactivity after 
percutaneous coronary intervention 
Dual antiplatelet therapy with aspirin and clopidogrel reduces recurrent thrombotic events 
in patients after acute coronary syndrome and percutaneous coronary intervention (PCI). (35; 
38) Clopidogrel is an adenosine diphospate (ADP) receptor antagonist that exerts its 
antiplatelet action via irreversible binding to the platelet P2Y12 receptor after metabolic 
activation, through the cytochrome P450 enzymes. Numerous reports have found that the 
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antiplatelet efficacy of clopidogrel exhibits considerable inter-individual variability. (41; 50) 
According to our current understanding, the insufficient and highly unpredictable generation 
of its active metabolite is largely responsible for the inter-individual differences observed in 
post-treatment platelet reactivity. (51) As the active metabolite formation is influenced by 
genetic, clinical and pharmacological factors, the development of high on-clopidogrel 
platelet reactivity (HPR) is a multifactorial process. (52) As recently evidenced, low compliance 
is also a remarkable reason for measuring HPR in the patient. (53) Up to now, numerous in 
vitro or ex vivo laboratory assays have been developed to monitor on-clopidogrel platelet 
reactivity. (54) Using these assays, accumulating number of observational studies have found 
that patients with HPR have higher risk for recurrent ischemic events, including myocardial 
infarction and stent thrombosis (ST). (55; 39; 56; 57; 58; 59; 60; 42; 61; 62) (63; 64; 65; 66; 67; 68; 69; 70; 71; 72) 
However, routine platelet function testing is not yet recommended. (73) First, this is due to 
the somewhat arbitrary-used and non-standardized definitions for HPR. Second, the 
prognostic significance of HPR after PCI is unclear as prospective, adequately-powered 
clinical trials are lacking. Third, there is no consensus on the ideal platelet function assay to 
monitor on-clopidogrel platelet reactivity. In the current review and meta-analysis, we 
aimed to collect and summarize the available evidence regarding the prognostic significance 
of HPR to achieve greater statistical power and more precise estimates. 
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3 Aims 
The main goal of the thesis to systematically overview and analyze the available medical 
literature, which reported clinical outcomes after revascularization procedures: 
Percutaneous coronary intervention (PCI) is routinely preformed through the femoral 
approach, which was the gold-standard method. Nevertheless, this access route 
accompanies higher rate of bleeding complications. Transradial approach has a lower 
incidence of bleeding complications. However requires longer learning curve and might 
increase the procedural time and more importantly the time to reperfusion, and the rate of 
procedural failure. Therefore our aim was to perform a systematic review of the literature 
comparing the safety and efficacy of the two vascular accesses.  
Antiplatelets prevent the recidive ischaemic events after PCI, but among patients, who 
require urgent surgical revascularization, the antiplatelet regime increases the risk of 
bleeding complications after operation. The higher rates of blood product transfusion may 
have an effect on morbidity and mortality. For that reason our aim was to evaluate the 
impact of preoperative administered clopidogrel on the outcome of patients referred for 
surgical revascularization. 
Several studies reported data about insufficient clopidogrel therapy, inter-individual 
differences on clopidogrel responsiveness. In case of non-responsiveness the incidence of 
adverse event corresponds with clopidogrel naive patients. Accordingly our aim was to 
collect and summarize the available evidence regarding the prognostic significance of high 
on-clopidogrel platelet reactivity. 
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4 The proposed meta-analyses 
4.1 Transradial PCI in acute MI 
4.1.1 Search strategy 
We performed a systematic review of the available literature according to the MOOSE 
guidelines for the conduct of meta-analyses of observational studies. (74) Relevant studies 
published between January 1993 and August 2009 were identified from MEDLINE®, 
SCOPUS®, the Web of Science® with Conference Proceedings, and the Cochrane Central 
Register of Controlled trials (CENTRAL) using a search strategy that combined text word and 
MeSH heading. Search keywords included various combinations of the following terms: 
“transradial”, “radial access”, “myocardial”, “infarct*“, and “coronary”. No language 
restrictions were imposed. Furthermore, we searched reference lists of relevant studies and 
reading reviews and editorials on this topic. In addition, relevant abstracts and presentations 
from the annual meetings of the American Heart Association, the American College of 
Cardiology, the European Society of Cardiology and Transcatheter Cardiovascular 
Therapeutics were identified. 
4.1.2 Selection criteria 
Inclusion criteria for retrieved studies were a) controlled comparison of the radial- versus 
femoral approach for coronary intervention b) in acute myocardial infarction (either 
primary- or rescue PCI) and c) intention-to-treat analysis. Exclusion criteria were a lack of 
clear- and reproducible results and incomplete follow-up, and lack of clear distinction of the 
clinical setting of the patients included (i.e. separate data for the acute- and elective 
interventions included). 
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4.1.3 Data abstraction and validity assessment 
Data abstraction was independently performed by two unblinded reviewers on pre-specified 
structure collection forms. Disagreements were resolved by consensus and discussion with a 
third party. Individual researchers were contacted in the case of incomplete reporting. The 
quality of study was evaluated by a third investigator according to a score, modified from 
Jadad et al. and Biondi-Zoccai et al. (13; 14; 15) 
4.1.4 Study outcome measures 
The primary clinical outcomes of interest, evaluated at the longest available follow-up, were 
1) mortality; 2) major adverse cardiovascular- and cerebrovascular events (MACE), including 
death, recurrent myocardial infarction, emergency percutaneous coronary intervention (PCI) 
or coronary artery bypass graft surgery (CABG), and stroke; 3) major bleeding (a 
standardized major bleeding definition was used that was adapted from the meta-analysis of 
Jolly et al. Briefly, major bleeding was defined as one of the following: fatal bleeding, 
intracranial hemorrhage, or bleeding associated with a ≥3 g/dL hemoglobin drop or requiring 
transfusion or requiring surgery (pseudoaneurysms requiring thrombin injection or 
ultrasound compression were excluded). For trials where the composite definition was not 
available, either transfusion rates or proportion of bleeding events associated with a ≥3 g/dL 
hemoglobin drop were substituted for major bleeding. Secondary procedural outcomes, 
pooled from individual studies when available, were: procedural time (in minutes), door-to-
reperfusion time (in minutes), fluoroscopy time (in minutes), length of hospital stay (in days), 
and access site crossover. 
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4.1.5 Data analysis and synthesis 
Dichotomous variables are reported as proportions and percentages, and continuous 
variables as mean values and standard deviation. Binary outcomes from individual studies 
were combined with the Mantel-Hansel fixed effect model, and the DerSimonian and Laird 
random effects model was used for sensitivity analysis. Continuous variables were compared 
with the inverse-variance method to obtain the mean difference and its confidence interval 
in a fixed-effect method. (75) The odds ratio (OR) and 95% confidence interval (CI) were used 
as summary statistics for the comparison of dichotomous variables between the radial- and 
femoral approaches. The mean difference (MD) and 95% CI were used for the continuous 
variables. Reported values were two-tailed, and hypothesis testing results were considered 
statistically significant at p value <0.05. Statistical analysis was performed using the Review 
Manager 5.0.16 developed and maintained by the Cochrane Collaboration. (75) We planned 
to conduct sensitivity analyses if significant heterogeneity was found (I2) for any of the 
outcomes. Sensitivity- and subgroup analyses were performed using the following 
categories: 1) randomized and observational studies 2) primary PCI and rescue PCI (studies 
with >50% of the patients undergoing PCI were included in this group) 3) cohorts whose use 
of GP IIb/IIIa inhibitor was below and over 15% 4) quality studies whose scores were higher 
than median and median versus lower than median. 
4.1.6 Search results and study selection 
Our search detected 213 citations. These included editorials, reviews, letters, or articles 
regarding other aspects of the radial approach. There were 62 observational studies 
investigating the feasibility and safety of the radial approach in a series of patients. 
Moreover, we found 13 studies comparing the radial- and femoral approaches in a cohort of 
patients that included both elective- and acute cases without reporting separate outcomes 
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regarding the different settings. Twelve studies were included in the final analysis. (Figure 1) 
These comprised 5 randomized trials involving 516 patients: 266 of the transradial- and 250 
of the transfemoral approaches. (76; 24; 77; 78; 79) Seven further reports using the registry 
approach of single- or dual center experiences of primary TRPCI were identified. These 
included 2808 cases, made up of 1212 transradial- and 1596 transfemoral interventions. (80; 
81; 82; 83; 30; 84; 85) All studies were published in peer-reviewed journals. (Table 4) The mean age 
was 60.9 years. On average, males accounted for 77.3% of subjects. The sheath size used 
was predominantly 6F or 6-7F. In four studies, sheaths allowed for the vascular access were 
smaller, 5-6F or 5-7F; in one other, a larger size 6-8F was used. In seven reports only primary 
PCI cases were presented, while 3 studies included also patients after systemic thrombolysis, 
and 2 further reports involved only patients with rescue PCI. All studies reported that 
unfractionated heparin (UFH) was administered intravenously in all cases except for two 
where use of enoxaparine was also allowed. GP IIb/IIIa usage was allowed in ten studies; the 
proportion of use varied from 21.2% to 100%. (Table 4-5). All studies reported data on the 
in-hospital follow-up, apart from four in which follow-up data were recorded for 30 days (24; 
84; 83; 79), and in one for nine months (78). 
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1. Figure: Flowchart of trials 
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4. Table: Details of trials 
Abbreviations: PCI: percutaneous coronary intervention, GP IIb/IIIa: platelet glycoprotein IIb/IIIa inhibitor, NA = not 
available, † aspirin plus thienopyridine, LD: loading dose, MD: maintenance dose, UFH: unfractionated, *heparin dosing 
monitored and adjusted to ACT 
  
Study 
(Published 
year) 
Methods 
Number 
of 
patients 
Mean 
age 
(years) 
Males 
(%) 
Rescue 
PCI (%) 
GP 
IIb/IIIa 
(%) 
Antithrombotic 
Treatment 
(LD/MD) † 
TEMPURA 
Saito et al. 
(2002) 
Single center 
randomized 
prospective 
149 67 81.2 0 0 
Ticlopidine 
UFH:6000 IU for 
males 
5000 IU for females 
Valsecchi et 
al. 
(2003) 
Single center 
prospective 
726 61.5 76 0 21.2 
Ticlopidine 
UFH: 70 IU/kg* 
Philippe et al. 
(2004) 
Single center 
prospective 
119 59.6 73.9 0 100 
Clopidogrel 300/75) 
UFH: 70 IU/kg 
RADIAL- AMI 
Cantor et al. 
(2004) 
Multicenter 
randomized 
50 55 88 66 94 
Clopidogrel (300/75) 
UFH: all patients*, 
dose NA 
Díaz de la 
Llera et al. 
(2004) 
Single center 
prospective 
162 57.2 85.2 17.9 67.3 
Clopidogrel (300/75) 
UFH: 5000 IU 
Kassam et al. 
(2004) 
Dual center 
retrospective 
111 56 79.3 100 100 
Clopidogrel (300/75) 
UFH: 60-70 IU/kg* 
Kim et al. 
(2005) 
Single center 
retrospective 
352 62.7 65.1 0 NA 
Ticlopidine or 
Clopidogrel (LD:300) 
UFH:70 U/kg or 30 
mg enoxaparin 
FARMI 
Brasselet et 
al. 
(2007) 
Single center 
randomized 
114 59 82.4 42.1 100 
Clopidogrel (300/75) 
UFH: 50 IU/kg 
(in cases w/ >75 
years upper limit 
4000 IU) 
or 30 mg enoxaparin 
iv. and 1mg/kg sc. 
RADIAMI 
Chodor et al. 
(2007) 
Single center 
randomized 
100 59.5 68 0 43 
Antiplatelets NA 
UFH: 70 IU/kg* 
Cruden et al. 
(2007) 
Single center 
retrospective 
287 59 82.9 100 93 
Clopidogrel (300-
600/75) 
UFH: 5000 IU or 70 
IU/kg 
Yan et al. 
(2008) 
Single center 
randomized, 
103 70.8 74.8 0 100 
Clopidogrel (600/75) 
UFH:70 IU/kg 
Hetherington 
et al. 
(2009) 
Single center 
retrospective 
1051 63.2 71 0 92.2 
Clopidogrel (600/75) 
UFH:70 IU/kg 
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5. Table: Details of trials 
Abbreviations: TRI = transradial intervention, NA = not available, IABP: intra aortic balloon pump, PM: pacemaker, #: 
report from centers with transradial PCI expertise, applying transradial access as first choice for PCI, •: operators with 
different expertise included 
  
(Published 
year) 
Sheath size 
Eligibility 
test 
Exclusion 
criteria 
Operators 
experience 
Follow 
up 
Quality 
score 
TEMPURA 
Saito et al. 
(2002) 
6 F Allen 
Cardiogenic shock, 
thrombolytic 
therapy 
>80% TRI cases 
of PCI/year 
In hospital 
and 9 
month 
9 
Valsecchi et 
al. 
(2003) 
6 F Allen 
History of CABG 
with both IMA, 
chronic renal 
failure 
>400 TRI 
cases/year 
In hospital 7 
Philippe et al. 
(2004) 
5-6 F Allen 
Cardiogenic shock, 
history of CABG 
>143 PCI 
cases/year 
30 days 7 
RADIAL- AMI 
Cantor et al. 
(2004) 
6-7 F Allen 
Cardiogenic shock, 
contraindication of 
GP IIb/IIIa use 
100 TRI cases 30 days 9 
Díaz de la 
Llera et al. 
(2004) 
6 F 
Allen, Pulse 
oxymetry 
Cardiogenic shock Institutional# 30 days 8 
Kassam et al. 
(2004) 
5-7 F NA NA Institutional In hospital 6 
Kim et al. 
(2005) 
6-8 F Allen 
Killips state 4, 
history of chr. renal 
failure 
>200 PCI 
cases/year 
In hospital 6 
FARMI 
Brasselet et 
al. 
(2007) 
5-6 F 
Allen, Pulse 
oxymetry 
Killip state > 2,  
GpIIb/IIIa 
intolerance, history 
of CABG, need for 
IABP or PM 
>100 TRI cases In hospital 7 
RADIAMI 
Chodor et al. 
(2007) 
6 F 
Allen, Pulse 
oxymetry 
Killip state > 2,  
history of CABG, 
need for IABP or 
PM 
50-100 TRI 
cases 
In hospital 8 
Cruden et al. 
(2007) 
NA NA NA 
>100 TRI 
cases/year 
In hospital 5 
Yan et al. 
(2008) 
6-7 F Allen 
Cardiogenic shock, 
chronic renal 
failure 
>500 TRI cases 30 days 8 
Hetherington 
et al. 
(2009) 
5-7 F NA Cardiogenic shock NA• In hospital 8 
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4.1.7 Clinical results 
The radial approach reduced risk for major bleeding by 70% compared to TFPCI (0.77% vs 
2.61%, OR: 0.30 [95% CI: 0.16, 0.55] P=0.0001; Figure 2). Reductions in the composite of 
death, myocardial infarction, and stroke were also significant (3.65% vs. 6.55%, OR: 0.56 
[95% CI: 0.39, 0.79] P = 0.001; Figure 3). Pooling the 29 events (2.59%) of 1421 TRPCI and 55 
(3.18%) of 1800 TFPCI demonstrated a significant mortality reduction in the case of TRPCI 
(OR: 0.54 [95% CI: 0.33, 0.86] P=0.01; Figure 4). There were no differences in procedural 
time and in time to reperfusion between the two access routes. Fluoroscopic times were 
longer in case of TRPCI; however, there was significant heterogeneity among studies in these 
parameters. Access site crossover was less frequent in the case of the transfemoral 
approach while the total hospital charge, assessed in eight studies was lower in the case of 
the transradial (Figure 5). 
2. Figure: Overall risk of major bleeding 
Abbreviations: CI: confidence interval; OR: odds ratio 
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3. Figure: Overall risk of major adverse events (MACE) 
Abbreviations: CI: confidence interval; OR: odds ratio 
 
4. Figure: Overall risk of death 
Abbreviations: CI: confidence interval; OR: odds ratio 
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5. Figure: Summary of outcomes of secondary endpoints radial versus femoral access for coronary intervention in 
myocardial infarction 
CI: confidence interval, * Odds ratio [CI 95%] 
OR calculations were also performed according to a random effects model, yielding similar 
results with regard to both the direction and magnitude of overall effects. Stratification and 
sensitivity analysis excluding non-randomized studies showed results similar to those of the 
comprehensive analysis. Findings were also comparable after pre-specified stratification in 
studies involving high-risk patients (i.e. studies that included >30% of patients with 
preceding thrombolysis, and with >90% use of GP IIb/IIIa inhibitors) and higher than median 
versus lower than median quality studies (Table 6). 
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6. Table: Subgroup and sensitivity analyses 
 Nr. of 
studies 
(Nr. of 
cases) 
Odds ratio [95% Confidence interval] 
Subgroup 
analysis 
(P value) 
 MACE Death Major bleeding 
Overall effect 
Random 
effect model 
11 
(3324) 
0.57 [0.40, 
0.81]** 
0.54 [0.34, 
0.88]* 
0.31 [0.17, 
0.59]** 
Randomization 
Randomized 
studies 
5 (516) 0.65 [0.32, 1.30] 
0.63 [0.25, 
1.58] 
0.49 [0.18, 1.31] 
Non-
randomized 
studies 
7 (2808) 
0.53 [0.35, 
0.80]** 
0.51 [0.29, 
0.88]* 
0.22 [0.10, 
0.50]** 
Rescue PCI 
>30% Rescue 
PCI 
4 (562) 0.53 [0.24, 1.17] 
0.71 [0.25, 
2.03] 
0.49 [0.19, 1.28] 
<30% Rescue 
PCI 
8 (2762) 
0.56 [0.38, 
0.83]** 
0.50 [0.30, 
0.85]* 
0.21 [0.09, 
0.48]** 
GPIIb/IIIa use 
>90% 
GPIIb/IIIa use 
7 (1835) 
0.53 [0.33, 
0.84]** 
0.54 [0.27, 
1.09] 
0.38 [0.16, 0.88]* 
<90% 
GPIIb/IIIa use 
5 (1489) 
0.60 [0.35, 
1.01+• 
0.53 [0.28, 
1.00]# 
0.23 [0.09, 
0.56]** 
Quality score 
High-quality 
studies 
(QS≥7) 
6 (1615) 
0.54 [0.33, 
0.86]* 
0.51 [0.27, 
0.97]* 
0.31 [0.11, 0.87]* 
Low-quality 
studies 
(QS<7) 
6 (1709) 
0.58 [0.35, 
0.97]* 
0.57 [0.28, 
1.13] 
0.32 [0.15, 
0.67]** 
Abbreviations: MACE: major adverse cardiovascular and cerebrovascular events, PCI: percutaneous coronary 
intervention, GP IIb/IIIa: platelet glycoprotein IIb/IIIa inhibitor, QS: quality score, •: p=0.06, #: p=0.05, *: p<0.05, **: 
p<0.01 
 
4.1.8 Limitations 
One major drawback is that the available literature consists only of a small number of 
studies and these studies themselves are often small in sample. Furthermore, the 
observational studies on this topic did not publish adjusted odds ratios. Consequently, 
although pooling adjusted risk estimates could have been more appropriate, we could only 
perform analyses using the reported event rates. Similarly the exclusion of different patient 
groups which might represent an inclusion bias in most of the studies is also an important 
issue. Patients suffering shock and with need for intraaortic balloon pump (IABP) insertions 
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were generally excluded from the studies and treated via the femoral route. Indeed IABPs, 
percutaneous assist devices, and some novel first generation interventional devices are too 
large to be used via the radial artery. IABP treatment is generally started during the 
procedure requiring double access site, and is only rarely introduced via the same line after 
PCI. There is no question as to whether the use of double groin puncture increases the risk 
of bleeding. Conversely, it is yet to be established whether sparing the femoral puncture site 
for the IABP and use of the radial route for the intervention — in cases where the artery is 
palpable and accessible for puncture — reduces the probability of bleeding. Of note is a 
recent meta-analysis that raised serious concerns on the need for IABP in the setting of 
primary PCI, including those with cardiogenic shock. (86) 
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4.2 Cardiac surgery related bleeding 
4.2.1 Search strategy 
We performed a systematic review of the available publications according to the MOOSE 
guidelines, to conduct meta-analyses of observational studies. (74) PubMed and Central 
databases were searched for relevant studies between January 2001 and May 2010. Search 
key words included various combinations of the following terms: CABG, clopidogrel, 
prognosis, bleeding, transfusion, reoperation, and mortality. No language restriction was 
used. Furthermore, we searched the reference lists of relevant studies and reviews, 
editorials, and letters on this topic. 
4.2.2 Selection criteria 
We selected all relevant studies which reported clinical outcomes after cardiac surgery in the 
context of preoperative clopidogrel administration. The primary clinical outcomes of 
interest, evaluated at the longest available follow-up, were mortality, red blood cell (RBC) 
transfusion, major bleeding, reoperation, and myocardial infarction (MI). Major bleeding was 
defined as an excessive chest tube bleeding at least over 500 ml. Inclusion criteria for 
retrieved studies were clopidogrel treatment within 0 to 7 days before surgical 
revascularization. Selection and data abstraction were done independently by two reviewers 
on pre-specified structure collection forms. Disagreements were resolved by consensus and 
discussion with a third party. The Newcastle Ottawa quality scoring system was used for 
quality assessment of the cohort reports. (75) 
4.2.3 Data analysis and synthesis 
Statistical analysis was performed using the Review Manager 5.0.23 freeware package 
maintained by the Cochrane Collaboration. (75) Odds ratios (OR) adjusted for the relevant 
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clinical parameters, from individual studies, were pooled with the random-effect model with 
the help of generic-inverse variance-weighting. If adjusted OR was not reported, it was 
calculated from the reported event frequencies and pooled with the random-effect model 
with the help of generic-inverse variance-weighting. Heterogeneity was quantified with a 
Chi2 heterogeneity statistics and by means of I2. 
4.2.4 Search results and study selection 
 Our search resulted in 115 citations. These included reviews and articles that did not match 
our inclusion criteria. After evaluation of abstracts, twenty-one potentially appropriate 
studies were found. One of these had lack of controlled comparison of clopidogrel treated 
patients with control group and was excluded after full text evaluation. Finally, twenty 
articles were selected for data extraction and analysis. (Figure 6) Among these, there was 
one smaller randomized study involving 136 patients (87); the further were observational 
trials that included 23,532 patients. Of the 20 reports, fifteen studies reported data on 
mortality (88; 89; 90; 91; 92; 93; 94; 95; 96; 87) (97; 98; 99; 100; 101); fourteen reported data on the need for 
blood transfusion (88; 89; 90; 91; 93; 95; 96; 87; 97; 102) (98; 99; 100; 101); 16 presented data on bleeding 
complications-related reoperations (88; 89; 91; 92; 93; 103; 94; 95; 96; 87) (104; 98; 105; 99; 100; 101); 6 studies 
reported data on major bleeding (89; 90; 87; 100; 105; 98) and other 9 studies investigated the 
frequency of postoperative myocardial infarction (88; 99; 91; 93; 95; 96; 87; 104; 100). Altogether the 
studies involved 23,668 patients.  
The mean age was 64.27 years. On average, female gender accounted for 26.19% of the 
subjects. The use of off-pump coronary artery bypass grafting (OPCAB) technique was 
reported in 9 trials. (88; 89; 90; 94; 95; 96; 93; 98; 99) The mean rate of OPCAB was 33.1%. Glycoprotein 
IIb/IIIa inhibitors were administered in 6 studies. (94; 95; 96; 97; 46; 98) In further 9 reports 
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aprotinin usage was allowed. (89; 93; 94; 102; 46; 90; 98; 105; 99; 100) Two studies reported the use of 
factor VII supplementation. (93; 46) All studies reported data on the in-hospital follow-up, 
while in ten studies; follow-up data were available for 30 days and in one study, for one year 
(Table 7). 
6. Figure: Flowchart of study selection 
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7. Table: Details of the selected trials  
Study 
(Publication 
year) 
Design 
Number 
of 
patients 
Indication 
for CABG 
Female 
(%) 
Mean 
age 
(yrs) 
Clopidogrel 
therapy (%) 
Clopidogrel 
exposure 
before surgery 
(days) 
Aspirin 
therapy 
(%) 
GP 
IIb/IIIa 
use (%) 
Aprotinin 
use (%) 
DM 
(%) 
Rate of 
OPCAB 
(%) 
Follow-up 
Quality 
score 
Yende 
(2001) 
Prospective 247 All comer 35.93 63.35 20.81 NA 72.69 6.6 65.3 32.29 24.5 1 month 7 
Hongo 
(2002) 
Prospective 224 Elective 26.78 66.95 26.34 < 7 61.60 NA NA NA NA In-hospital 8 
Ray (2003) Retrospective 659 All comer 24.13 66.25 24.58 < 7 22.91 NA • NA NA In-hospital 6 
Englberger 
(2004) 
Prospective 505 All comer 22.77 67 26.93 < 3 NA NA 100 NA 14.06 1 month 8 
Karabulut 
(2004) 
Prospective 1628 All comer 21.31 62.05 2.95 < 2 64.62 NA NA 22.30 0 In-hospital 6 
Kapetanakis 
(2005) 
Prospective 2359 All comer 27.13 64.45 17.59 < 7 NA NA 1.3 34.34 66.63 1 month 9 
Leong 
(2005) 
Prospective 919 All comer 23.83 63.82 9.25 < 7 71.70 1.1 NA 30.68 11.86 1 month 10 
Nurozler 
(2005) 
Prospective 182 Urgent* 26.92 63.75 42.30 < 3 64.28 NA NA 20.33 0 In-hospital 6 
CRUSADE 
(2006) 
Prospective 2858 Urgent** 11.37 66.25 29.81 < 5 vs. >5 95.10 40.58 NA 33.41 NA In-hospital 8 
CLARITIY-
TIMI 28 
(2007) 
Randomized 136 Urgent† 17.6 59.4 48.53 <5 vs. >5 NA NA NA 20.5 NA 1 month NA 
Kang (2007) Prospective 320 All comer 28.75 65.14 20.31 <3 and <7 100 NA NA NA NA In-hospital 7 
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Ouattara 
(2007) 
Prospective 217 Elective 37.06 65.5 27.65 <5 100 NA 100 35.48 0 In-hospital 7 
Berger 
(2008) 
Retrospective 596 Urgent** 31.71 64 100 <5 vs. >5 91.95 13.59 33.22 36.07 27.68 1 month 9 
Filsoufi 
(2008) 
Retrospective 144 All comer 40 63 50 <3 88.88 NA 6 50 26 In-hospital 7 
Kim (2008) Retrospective 4794 All comer 29.9 64 8.28 <5 vs. >5 NA ‡ 8.76 34.8 14.5 1 month 9 
Maltais 
(2008) 
Retrospective 453 All comer NA 64 22.29 <7 100 9.93 NA NA 100 In-hospital 8 
ACUITY 
(2009) 
Prospective 1520 Urgent** 23.22 64.5 50.85 <5 vs. >5 97.76 NA NA 34.01 12.7 1 year 9 
Balasco-
Colmenares 
(2009) 
Retrospective 1677 All comer 27.19 65.35 13.08 <5 100 NA NA 32.2 NA 1 month 8 
Hermann 
(2010) 
Retrospective 3779 All comer 25.06 NA 26.43 <5 vs. >5 NA NA 10 35.48 NA In-hospital 6 
Nesher 
(2010) 
Retrospective 451 Urgent¥ 23.72 66 41.9 ≤5 NA NA 100 28.83 NA 1 month 9 
Abbreviations: NA: not applicable; *: critical left main coronary artery stenosis, critical left anterior descending artery stenosis, acute coronary syndrome; **: non ST-segment elevation myocardial infarction, 
acute coronary syndrome; †: ST-segment elevation myocardial infarction; ¥: did not defined; •: left to the discretion of the anesthetist and surgeon; ‡: not available rate of use; yrs: year 
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4.2.5 Clinical results 
We observed an increase in cardiovascular mortality among patients receiving clopidogrel 
before surgery (OR: 1.24; 95%CI: 1.03-1.49, p=0.03, Figure 7) that was not heterogeneous 
among studies (I2: 0%, Chi2: 4.68, p=0.99). Clopidogrel administration within 7 days before 
cardiac surgery was associated with a significant increase in the rates of RBC transfusions 
(OR: 1.82; 95%CI: 1.40-2.37; p<0.00001; Figure 8A) and in bleeding-triggered reoperations 
(OR: 2.15; 95%CI: 1.38-3.34; p<0.00001; Figure 8B).  However, these outcomes showed 
significant heterogeneity among studies (transfusion: I2: 84%, Chi2: 82.52, p<0.00001; 
reoperation: I2: 54%, Chi2: 30.69, p=0.006). According to subgroup analyses, the highest risk 
for RBC transfusion, major bleeding or reoperation was seen if the discontinuation of 
clopidogrel was shorter than 3 days prior to surgery. (OR: 7.56 (95%CI: 2.38-23.99); OR: 6.62 
(95%CI: 1.69-25.95) and OR: 3.40 (95%CI: 1.51-7.65), respectively). This higher risk for 
transfusion was less prominent when clopidogrel was discontinued earlier. In studies 
comparing the discontinuation before and after 5 days only a strong trend for higher rate of 
transfusion was found (OR: 1.36; 95%CI: 1.00-1.84; p=0.05; Table 8). Notably, Reoperation 
rates were significantly higher in studies published before 2006 (OR: 4.73; 95%CI: 3.01-7.45; 
p<0.00001; Figure 8B). There were no difference in the incidence of postoperative 
myocardial infarction between groups; however the pooled results were heterogeneous. 
(OR: 0.83; 95%CI: 0.44-1.57; p=0.57; Figure 9). 
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7. Figure: Overall risk of mortality 
Abbreviations: SE: standard error; CI: confidence interval 
 
8. Figure: Overall risk of transfusion (A) and reoperation subgroup analysis (B) 
Abbreviations: SE: standard error; CI: confidence interval 
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8. Table: Subgroup and sensitivity analyses 
Subgroup 
analysis (p 
value) 
    
Number of 
studies 
(number of 
participants) 
Odds ratio (95% CI) 
    
RBC transfusion 
Myocardial 
infarction 
Reoperation Mortality Major bleeding 
Discontinuation 
of clopidogrel 
prior to surgery 
<3 days• 5 (2779) 7.56 [2.38, 23.99]** 0.91 [0.15, 5.55] 3.40 [1.51, 7.65]** 2.66 [0.87, 8.08] 6.62 [1.69, 25.95]** 
<5 days¥ 14 (18807) 1.95 [1.31, 2.91]** 0.59 [0.44, 0.80]** 1.57 [0.99, 2.48] 1.23 [1.01, 1.49]* 1.14 [0.95, 1.37] 
<5 days vs. >5 days† 6 (7670) 1.36 *1.00, 1.84+‡ NA 1.90 [0.80, 4.49] 1.35 [0.82, 2.22] 1.32 [1.04, 1.68]* 
Aprotinin use 
Yes 10 (13751) 2.53 [1.57, 4.07]** 1.30 [0.23, 7.37] 2.89 [1.37, 6.10]** 1.20 [0.92, 1.58] 1.79 *0.99, 3.24+‡ 
No 10 (9917) 1.32 [1.08, 1.63]** 0.59 [0.43, 0.79]** 1.63 *0.99, 2.68+‡ 1.26 [0.98, 1.63] 0.98 [0.80, 1.20] 
GP IIb/IIIa use 
Yes 6 (9867) 1.44 [1.19, 1.75]** 0.50 [0.15, 1.64] 1.95 [1.03, 3.71]* 1.36 [0.98, 1.90] 1.73 [0.77, 3.89] 
No 14 (13801) 2.05 [1.36, 3.10]** 1.03 [0.45, 2.38] 2.19 [1.13, 4.26]* 1.16 [0.91, 1.47] 1.32 [0.91, 1.93] 
OPCAB 
Yes 9 (11537) 2.35 [1.33, 4.14]** 0.88 [0.31, 2.46] 2.42 [1.33, 4.38]** 1.32 [0.97, 1.79] 1.81 [0.74, 4.45] 
No 11 (12131) 1.53 [1.23, 1.89]** 0.69 [0.31, 1.52] 1.83 [0.93, 3.60] 1.19 [0.94, 1.51] 1.24 [0.91, 1.70] 
Quality score 
QS>7 11 (1) 1.76 [1.20, 2.59]** 0.75 [0.31, 1.81] 2.16 [1.31, 3.56]** 1.29 [1.02, 1.63]* 1.94 [0.63, 6.00] 
QS≤7 8 (71769) 2.00 [1.47, 2.72]** 0.91 [0.15, 5.55] 3.34 [1.34, 8.29]** 1.14 [0.83, 1.55] 1.38 [0.97, 1.96] 
*p<.05.; ‡p=.05.; **p<.01.; •: studies with shorter than 3 days exposure vs. no clopidogrel pretreatment; ¥: studies with shorter than 5 days exposure (including the group of the <3 days vs. no 
clopidogrel pretreatment); †: controlled comparison of the <5 days exposure group vs. >5 days exposure group; NA: not applicable 
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9. Figure: Overall risk of postoperative myocardial infarction 
Abbreviations: SE: standard error; CI: confidence interval 
 
4.2.6 Limitations 
There are several obvious limitations of this study. First, the number of the high-quality, 
randomized clinical trials was low in the analysis. Randomized studies are usually well-
balanced with regard to baseline characteristics of the enrolled patients; this is typically not 
the case for observational studies. Consequently, the analysis may inadvertently include 
some inclusion bias. In order to obviate selection bias, adjusted odds ratios are reported in 
some observational studies. To incorporate the adjustment, - where possible - adjusted ORs 
were pooled with logarithmic transformation according to a random-effect model via 
generic-inverse variance-weighting. 
Although the rates of bleeding-related complications are easy to calculate, the indication of 
red blood cell transfusion and reoperation might have been very arbitrary and might have 
differed markedly among studies. This aspect might have been reflected in the 
heterogeneity of the results. 
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4.3 Clinical relevance of high platelet reactivity 
4.3.1 Search strategy 
We performed a systematic review of the available publications according to the MOOSE 
guidelines, to conduct meta-analyses of observational studies. (74) Pub Med and Central 
databases were searched for relevant articles published between January 2003 and February 
2010. Search key words included various combinations of "clopidogrel" with the following 
terms: resistance, platelet reactivity, outcome and prognostic. No language restriction was 
used. We also searched the reference lists of relevant studies and reviews, editorials, and 
letters. In case of incomplete reporting, individual authors were contacted. 
4.3.2 Selection criteria 
We selected all relevant studies which met the following inclusion criteria:  
(1) Studies that recruited patients receiving aspirin and clopidogrel therapy after 
percutaneous coronary intervention (PCI); 
(2) Reported an intention-to-treat analysis on the clinical impact of HPR measured by an 
ADP-specific platelet function assay. No case-control studies were accepted. The accepted 
assays included ADP-stimulated light transmission aggregometry (LTAADP), flow cytometric 
assessment of vasodilator-stimulated phosphoprotein phosphorylation (VASP; PLT 
VASP/P2Y12 kit, Biocytex, Marseille, France), the VerifyNow device using P2Y12 cartridge 
(VerifyNowP2Y12; Accumetrics, San Diego, CA), and multiple electrode aggregometry with ADP 
stimuli (MEAADP; Dynabyte, Munich, Germany). In case of studies using more than one assay, 
two assays with the highest predictive values were selected. (58; 63; 72) 
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(3) All studies that measured platelet aggregation values after a loading dose or during the 
maintenance phase of clopidogrel therapy were eligible. Examinations that assessed 
responsiveness to clopidogrel, that is, a difference between baseline and post-treatment 
platelet reactivity (inhibition of platelet aggregation [IPA]), were excluded from the analysis. 
(Figure 10) 
10. Figure: Flowchart of study selection 
 
*
IPA: inhibition of platelet aggregation, calculated as the baseline aggregation minus post-treatment aggregation value 
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The primary clinical outcomes of interest, evaluated at the longest available follow-up 
(during which patients were on clopidogrel treatment) were (a) cardiovascular (CV) death, 
(b) definite/probable stent thrombosis (ST), (c) non-fatal myocardial infarction (MI) (Type 1, 
4a, 4b) and (d) a composite endpoint of the reported ischemic events (CIE) that included CV 
death, MI, ischemic stroke, unplanned repeat revascularization or rehospitalization for ACS. 
Those studies that evaluated solely periprocedural MI (Type 4b) were excluded. 
4.3.3 Data abstraction and analysis 
Selection and data abstraction were done independently by two reviewers on prespecified 
structure collection forms. Disagreements were resolved by consensus and discussion with a 
third party. Statistical analysis was performed using the Review Manager 5.0.22 freeware 
package maintained by the Cochrane Collaboration. (Review Manager [RevMan]. Version 
5.0.22 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.) Hazard 
ratios (HR) and odds ratios (OR) adjusted for the relevant clinical parameters, from individual 
studies, were pooled with the random-effect model via generic-inverse variance-weighting. 
If the adjusted relative risk was not reported, the odd ratios were calculated from the 
reported event frequencies. Heterogeneity was quantified with a Chi2 heterogeneity statistic 
and by means of I2. Group comparisons in case of the prevalence of HPR were done with the 
Kruskal-Wallis test. A p value < than 0.05 was considered significant. 
4.3.4 Study selection 
Our search resulted in 1801 citations. These included reviews and articles that did not meet 
our inclusion criteria. After careful title and abstract evaluation, 31 potentially appropriate 
studies were found. After excluding case-control analyses, studies that linked clopidogrel 
responsiveness (baseline minus post-treatment aggregation, IPA) to clinical outcome and 
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studies that reported solely the rate of periprocedural myonecrosis, 20 articles including a 
total number of 9,187 patients were selected for full text analysis and data extraction. (55; 39; 
56; 57; 58; 59; 60; 42; 61; 62) (63; 65; 64; 66; 67; 68; 69; 71; 72; 70) (Figure 10) Out these, thirteen studies reported 
platelet reactivity with LTAADP,
 (39; 55; 56; 58; 59; 42; 61; 62; 63; 65) (64; 66; 68) five with the VerifyNowP2Y12 
assay, (58; 60; 67; 69; 70) three used VASP phosphorylation (57; 63; 72) and two the MEAADP 
device (71; 72). Major characteristics of the included studies are depicted in Table 9. 
9. Table: Detailed description of the selected studies 
Investigator 
(Publication 
year) 
Design, patient 
profile 
Number 
of 
patients 
Laboratory 
methods 
Selected 
cutoff for 
HPR 
HPR 
(%) 
Clopidogrel 
LD / MD 
End 
point 
Follow-
up 
Quality 
score† 
Cuisset (2006) RCT, NSTEMI 146* 
LTA: 10µmol 
ADP, AGGmax 
AGGmax 
≥70% 
15.1 600 / 75 CIE 1 month NA 
Cuisset (2006) 
Prospective, 
NSTEMI 
106 
LTA: 10µmol 
ADP, AGGmax 
Highest 
quartile 
(AGGmax 
≥70%) 
21.7 300 / 75 CIE 1 month 9 
Geisler  (2006) 
Prospective, 
all-comer 
363 
LTA: 20µmol 
ADP, AGGmax 
AGGmax 
≥70% 
6.1 600 / 75 
D / MI / 
CIE 
3 months 9 
Hochholczer 
(2006) 
Prospective, 
stable angina 
802 
LTA: 5µmol 
ADP, AGGlate 
Above the 
median 
(AGGlate 
≥15%) 
49.3 600 / 75 
D / MI / 
CIE 
1 month 9 
Angiolillo 
(2007) 
Prospective, 
stable angina 
with DM 
173 
LTA: 20µmol 
ADP, 
AGGmax 
Highest 
quartile 
(AGGmax 
≥62%) 
26.0 0 / 75 CIE 2 years 9 
Bliden (2007) 
Prospective 
stable angina 
100 
LTA: 5µmol 
ADP, AGGmax 
AGGmax 
≥50% 
22.0 0 / 75 MI / CIE 1 year 9 
Bonello (2007) 
Prospective, 
stable/UA 
144 VASP: PRI 
Highest quintile 
(PRI >47%) 
79.9 300 / 75 D / CIE 6 months 9 
Buonamici 
(2007) 
Prospective, 
all-comer 
804 
LTA: 10µmol 
ADP, AGGmax 
AGGmax 
≥70% 
13.1 600 / 75 D / ST 6 months 9 
Frere (2007) 
Prospective, 
NSTEMI 
195 
VASP: PRI 
LTA:10µmol 
ADP, 
AGGmax 
PRI≥53% 
AGGmax 
≥70% 
(ROC-defined) 
54.4 
29.8 
600 / 75 CIE 1 month 9 
Aradi (2008) 
Prospective, 
stable/ UA 
108• 
LTA: 5µmol 
ADP, AGGmax 
Patients 
above the 
median 
(AGGmax 
>33%) 
51.9 300 / 75 
MI / ST / 
CIE 
10 
months 
9 
Patti (2008) 
Prospective, 
all-comer 
160 VerifyNow 
Highest 
quartile 
(>240 PRU) 
25.0 600 / 75 CIE 1 month 9 
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Abbreviations: ADP: adenosine 5'-diphosphate; AGGmax: maximal aggregation; AGGlate: late aggregation; AU: arbitrary 
unit; AUC: area under curve; CIE: composite ischemic events; D: cardiovascular death; DM: diabetes mellitus; LD: loading 
dose; LM: left main stenting; LTA: light transmission aggregometry; MEA: multiple electrode aggregometry; MI: non-fatal 
myocardial infarction; MD: maintenance dose; NA: not applicable; NSTEMI: non-ST-segment elevation MI; PRI: platelet 
reactivity index; PRU: platelet reaction unit; RCT: randomized controlled trial; ST: stent thrombosis; VASP: vasodilator-
stimulated phosphoprotein phosphorylation analysis; †: New Castle Ottawa score: quality assessment of observational 
studies; this scoring is not applicable for randomized, controlled trials; *: data from the 600-mg loaded group, •: data 
from clopidogrel-treated patients, #: patients on clopidogrel for at least 6 months, UA: unstable angina 
  
Price (2008) 
Prospective, 
all-comer 
317# VerifyNow 
≥235 PRU 
(ROC-
defined) 
34.1 600 / 75 
D / MI / ST 
/ CIE 
6 months 9 
Castro (2009) 
Prospective, 
NSTEMI 
161 VerifyNow 
>175 PRU   
(ROC-
defined) 
39.8 300 / 75 CIE 1 year 9 
Cuisset (2009) 
Prospective, 
NSTEMI 
598 
LTA  10 µmol 
ADP, AGGmax 
VASP, PRI 
AGGmax > 
67% (ROC-
defined) 
PRI: not 
reported 
30.9 600 / 75 ST 1 month 9 
Geisler (2009) 
Prospective, 
all-comer 
1019 
LTA: 20 µmol 
ADP, AGGlate 
Patients of 
the highest 
quartile 
(>42.5%) 
32.3 600 / 75 
D / MI ST 
/ CIE 
3 months 9 
Marcucci 
(2009) 
Prospective, 
ACS 
683 VerifyNow 
≥240 PRU   
(ROC-
defined) 
32.1 600 / 75 
D / MI / 
CIE 
1 year 9 
Migliorini 
(2009) 
Prospective, all-
comer (LM) 
215 
LTA: 10  µmol 
ADP, AGGmax 
AGGmax 
> 70% 
18.6 
600 / 75 
or 150 
D / MI ST 3 years 9 
Sibbing (2009) 
Prospective, 
all-comer 
1608 MEA: AUC 
Highest 
quintile 
(>416 AU) 
20.1 600 / 75 D / MI ST 1 month 9 
Siller-Matula 
(2009) 
Prospective, 
all-comer 
416 
MEA: AUC 
VASP: PRI 
AUC > 54 U    
PRI > 23 % 
(ROC-
defined) 
13.5 
63.0 
600 or 0 
/ 75 
ST 6 months 9 
Breet (2010) 
Prospective, 
stable angina 
1069 
LTA: 5 µmol 
LTA: 20 
µmol 
ADP, 
AGGmax 
VerifyNow 
AGGmax 
≥42.9% 
AGGmax 
≥64.5% 
≥236 PRU   
(ROC-defined) 
42.4 
37.3 
38.6 
300/75 
or 
600/75 
or 0/75 
D / MI ST 
/CIE 
1 year 9 
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4.3.5 Prevalence of high on-clopidogrel platelet reactivity 
In the 20 studies, including 9,187 patients, the rate of HPR showed large heterogeneity with 
a mean prevalence of 32.3% (95% CI for mean: 25.9–40.5; range: 6.06-79.86). To find 
possible determinants of the observed heterogeneity, the prevalence of HPR was analyzed 
according to the following grouping factors: type of platelet function device, the selected 
platelet reactivity cutoff, the amount of clopidogrel loading dose, time of assessment from 
loading/last clopidogrel dose, proportion of acute coronary syndrome patients in each 
group. (Table 10) Among the recruited studies, the selected platelet reactivity cutoff and the 
type of the platelet function device interacted significantly with the prevalence of HPR 
(Kruskal-Wallis test: P=0.04 and P=0.02, respectively; Table 10). The selected cutoff was in 
strong, inverse correlation with the rate of HPR. (Figure 11A) Among the devices, the most 
P2Y12-specific assay (VASP) indicated the highest rates of HPR. 
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10. Table: Prevalence of high on-clopidogrel platelet reactivity (HPR) 
Intergroup comparisons were done with the Kruskal-Wallis test. 
*
: The POPULAR study (106) was not included as 
recruited patients received three different clopidogrel regimens. † For the comparison, 2 continuous variables (platelet 
reactivity cutoff and proportion of ACS patients) were divided into tertiles, which means dividing ordered data into 3 
essentially equal-sized data subsets. ‡ Whereas LTAADP and VASP measure platelet reactivity in a 0% to 100% scale, 
results might range between 18 and 435 PRU in case of VerifyNowP2Y12 and between 0 and 122 U in case of MEAADP assay 
according to the description of the manufacturer. Thereby, results of the VerifyNowP2Y12 and MEAADP assays were 
normalized to a 0 to 100 scale, where the lowest potential value (18 PRU and 0 U) reflects 0% and the highest potential 
value (435 PRU and 122 U) means 100%. 
  
 
Mean, % (95% CI) P 
Overall 33.2 (25.9 – 40.5)  
Platelet Function Method    
MEAADP: 
LTAADP: 
VerifyNOWP2Y12: 
VASP: 
16.8 (-25.1 – 58.7) 
28.3 (20.5 – 36.1) 
33.9 (26.6 – 41.2) 
65.8 (33.5 – 98.0) 
 0.02 
Clopidogrel Loading Dose*   
0 mg (pre-treatment) 
300 mg 
600 mg 
24.0 (-1.4 – 49.4) 
48.3 (9.5 – 87.2) 
29.2 (20.2 – 38.1) 
0.27 
Time to assessment from 
loading/last dose of clopidogrel* 
  
<12 h 
12-18 h 
>18 h 
31.1 (20.4 – 41.9) 
28.7 (16.3 – 41.0) 
33.7 (-66.3 – 133.7) 
0.62 
Platelet reactivity cutoff for 
defining HPR (tertiles†)‡ 
  
14 – 45% 
46 – 62% 
63 – 70% 
39.0 (25.2 – 52.8) 
39.0 (22.8 – 55.2) 
21.6 (12.8 – 30.3) 
0.04 
Proportion of ACS patients 
(tertiles)  
  
0 – 25% 
25 – 80% 
80 – 100% 
37.1 (20.4 – 53.8) 
27.9 (5.3 – 50.4) 
32.0 (20.3 – 43.7) 
0.34 
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11. Figure: Impact of the methodological heterogeneity in platelet aggregation tests 
 
 
Impact of the methodological heterogeneity in platelet aggregation tests. A, Linear regression analysis between the 
selected cutoff and the prevalence rate for high platelet reactivity (HPR). Whereas LTAADP and VASP measure platelet 
reactivity in a 0% to 100% scale, results might range between 18 and 435 PRU in case of the VerifyNowP2Y12 and between 
0 and 122 U in case of MEAADP assay according to the description of the manufacturer. Thereby, results of the VerifyNow-
P2Y12 and MEAADP assays were normalized to a 0 to 100 scale, where the lowest potential value (18 PRU and 0 U) reflects 
0% and the highest potential value (435 PRU and 122 U) means 100%. B, The impact of the prevalence rate of HPR on the 
relative risk of CV death. 
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4.3.6 Prognostic significance of high on-clopidogrel platelet reactivity 
Of the 20 studies, ten reported data on cardiovascular death, (57; 58; 59; 65; 64; 66; 67; 68; 70; 71) ten 
on non-fatal myocardial infarction (39; 56; 58; 65; 64; 66; 70; 67; 68; 71) and nine on definite or probable 
stent thrombosis (ST) (39; 58; 62; 63; 64; 68; 70; 71; 72). Moreover, there were 15 studies that reported 
a composite event rate of the recurrent ischemic events (CIE) in compliance with our 
inclusion criteria (41; 39; 56; 57; 58; 60; 42; 61; 62; 63) (65; 66; 67; 69; 70). Based on the pooled results, HPR 
was associated with a significant, 3-fold increase in non-fatal MI (OR: 3.00; 95%CI: 2.26-3.99; 
p<0.00001; Figure 12B), a 4-fold increase in definite/probable ST (OR: 4.14; 95%CI: 2.74-
6.25; p<0.0001; Figure 12C) and a 5-fold increase in the rate of composite ischemic events 
(OR: 4.95; 95%CI: 3.34-7.34; p<0.00001; Figure 13). Importantly, patients with HPR defined 
by an ADP-specific platelet function assay had a 3.4-fold increase in cardiovascular mortality 
compared to those with normal on-clopidogrel ADP-reactivity (OR: 3.35, 95%CI: 2.39-4.70, 
p<0.00001; Figure 12A). When the subgroup of studies using receiver operating 
characteristic (ROC)-defined cutoffs for HPR was analyzed separately, similar outputs were 
gained (CV death 2.34 [1.40-3.92], MI 2.89 [2.07-4.04], ST 4.75 [2.13-10.63], and CIE: 3.06 
[2.07- 4.51]; P <0.001 in all cases). Although there was large methodical heterogeneity 
among the platelet function assays as well as in the selected cutoffs for HPR, the predicted 
risk for CV death, non-fatal MI and ST were not heterogeneous between studies (Figure 12). 
On the contrary, there was significant heterogeneity in case of the less standardized, 
composite end point (Figure 13). 
When the predictive value of each assay was analyzed separately, only LTA-defined HPR was 
significantly associated with CV death, MI, and ST (death: 4.18 [2.70-6.46], MI: 2.93 [1.97-
4.35], ST: 3.66 [2.32-5.78]; P<0.0001 in all cases). The VerifyNowP2Y12 predicted CV death and 
MI (death: 2.28 [1.23-4.25], P=0.009; MI: 2.98 [1.94-4.58], P<0.00001), but only a trend was 
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observed regarding ST (4.17 [0.81-21.63], P=0.09). MEAADP significantly predicted MI and ST 
(MI: 4.03 [1.16-14.00], P=0.03; ST: 13.89 [2.63-73.45], P =0.002), but only a trend was 
observed regarding CV death (3.21 [0.86-12.00], P=0.08). Based on the results of 2 small 
studies, VASP-defined HPR was predictive neither for CV death (1.84 [0.09-37.07], P=0.69) 
nor for ST (1.48 [0.28-7.77], P =0.64). 
Because of the large differences in the methodology, terminology, as well as the patient 
selection and follow-up, we performed subgroup analyses among the studies that reported 
composite outcome results (Figure 14). The analysis confirmed that all of the selected ADP-
specific assays were able to predict the occurrence of CIE, and the worse prognosis of 
patients with HPR was consistent regardless of the clinical presentation and the length of 
follow-up. Notably, there was significant heterogeneity in the results between studies using 
optical aggregometry; however, the more standardized methods, such as the VerifyNowP2Y12 
and VASP assay, showed more homogenous findings. 
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12. Figure: Impact of high on-clopidogrel platelet reactivity (HPR) on the occurrence of cardiovascular (CV) death (Panel 
A), non-fatal myocardial infarction (MI, Panel B) and definite or probable stent thrombosis (Panel C) 
The odds ratios (OR) with 95% confidence intervals (95% CI) were calculated from event frequencies with the random-
effect model via generic inverse variance-weighting. LTA: light transmission aggregometry; MEA: multiple electrode 
aggregometry; NPR: normal platelet reactivity; VASP: vasodilator-stimulated phosphoprotein phosphorylation 
assessment. 
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13. Figure: Impact of high on-clopidogrel platelet reactivity (HPR) on the occurrence of composite ischemic events (CIE) 
Where possible, adjusted odds ratios (OR) with 95% confidence intervals (95%CI) were used in the random-effect model 
via generic inverse variance-weighting. 
*
: studies not reporting adjusted OR-s. LTA: light transmission aggregometry; 
NPR: normal platelet reactivity; VASP: vasodilator-stimulated phosphoprotein phosphorylation assessment. 
 
14. Figure: Sensitivity and subgroup analyses among studies that linked post-treatment platelet reactivity to the 
occurrence of composite ischemic events 
ACS: acute coronary syndrome; LTA: light transmission aggregometry; PCI: percutaneous coronary intervention VASP: 
vasodilator-stimulated phosphoprotein phosphorylation 
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4.3.7 Limitations 
Our analyses have some obvious limitations. The meta-analysis included observational 
studies that are usually unbalanced with regard to baseline clinical characteristics of the 
patients. Although observational studies could better reflect the real-world practice, lack of 
monitoring drug compliance, underreporting a negative result, and incomplete follow-up 
make their interpretation more difficult and might carry ascertainment biases. To control for 
possible confounding factors, adjusted risks were used where possible; and data were 
pooled with logarithmic transformation according to a random-effect model via generic 
inverse variance weighting. Although these factors might have an impact on the magnitude 
of the observed ORs, they did not influence the prevalence rate of HPR and were not 
thought to have biased the overall analysis. It is also notable that the patients were not 
treated uniformly regarding the loading doses of clopidogrel and that platelet function 
assessments were performed at different time points after PCI. One study also enabled the 
use of different antiplatelet strategies in the maintenance period, whereas none of the 
selected studies could reliably monitor compliance with the prescribed medication. In 
conclusion, this meta-analysis confirms that patients with HPR are at a heightened risk for CV 
death, MI, and ST after stent implantation. Whether HPR is a marker for adverse outcomes 
or a modifiable risk factor that can be diminished by more aggressive antiplatelet strategies 
remains to be established by the ongoing, large-scale randomized trials (ARCTIC: 
NCT00827411, DANTE: NCT00774475, DOSER: NCT00638326, GRAVITAS: NCT00645918, 
TRIGGER-PCI: NCT00910299) 
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5 Novel findings of the thesis 
Main findings of the thesis are the followings: 
Transradial percutaneous coronary intervention reduces the risk of periprocedural 
major bleeding and major adverse events in the ST-elevation acute myocardial infarction 
setting. The difference between two access routes was represented in clinically insignificant 
differences is procedural time and in time to reperfusion. Nevertheless the mortality 
significantly decreased in transradial route. 
Clopidogrel pre-treatment of patients before cardiac surgery, increases the risk of 
major bleeding. A trend for improvement can be observed in the frequency of the need for 
reoperation. However perioperative care and surgical practice seems to adapt the changed 
medication protocol. Our meta-analysis found statistically significantly increased risk for 
mortality among clopidogrel pretreated patients. 
High on-clopidogrel platelet reactivity, measured by an ADP-specific platelet function 
assay after percutaneous coronary intervention, is a strong predictor of cardiovascular 
death, myocardial infarction and stent thrombosis in patients after percutaneous coronary 
intervention. Although there were large differences in the methodology, patient selection 
and cutoff definition between studies, the predicted risk of cardiovascular death, myocardial 
infarction and stent thrombosis were not heterogeneous. 
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6 Discussion 
The meta-analysis of studies investigating the role of vascular access site in patients with ST 
elevation found that transradial coronary intervention is highly effective and safe in the 
setting of acute myocardial infarction. We demonstrated a significant benefit of using radial 
access for PCI in MI with respect to major bleeding as well as in major adverse events 
(MACE). These findings were consistent in the setting of primary- and rescue PCI. 
Bleeding events have been demonstrated to be associated with an increased risk of MACE 
including death and recurrent ischemic events in multiple studies. (31; 32; 107) Though the exact 
relation between bleeding events and higher mortality is unclear, obviating bleeding seems 
equally important as recurrent ischemic events after PCI. (45) Possible mechanisms of worse 
outcome after a bleeding event might include bleeding-induced imbalance of the 
coagulant/anticoagulant mechanisms, (consumption of the anticoagulant proteins, higher 
platelet turnover), adverse effects induced by transfusion, and premature cessation of 
antithrombotic/anticoagulant therapy. (21) As a consequence of the combined- and more 
potent anticoagulant and antiplatelet medications, bleeding is getting to be more frequent 
after acute intervention. Arterial puncture used for intervention is a predominant 
predilection site as the majority of bleeding originates from here. Reduction of the 
frequency of bleeding and mortality using the transradial approach has been recently 
demonstrated in a large registry study that included all-comers for PCI. (31) Similar reduction 
has been demonstrated in transradially treated cases in an observational study that included 
over a thousand non-ST segment elevation acute coronary syndrome patients. (108)  
Furthermore, two recent comprehensive meta-analyses of randomized comparisons of 
transradial- and transfemoral accesses demonstrated that radial access reduces bleeding 
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and access site complications. Neither of them found a significant link between the 
frequency of adverse events or mortality. It should be noted that these analyses included 
studies performed predominantly in elective settings and thus the benefit that the higher 
risk patients may have been concealed by the lower risk cases that may have formed the 
majority. 
Distrust supported by technical difficulties, higher failure rate, and increased radiation 
exposure still limits general acceptance of TRPCI. This uncertainty is graver in the setting of 
acute MI, when the delay caused by unsuccessful arterial access may adversely affect the 
clinical outcome. Agostoni et al. reported reduction of the entry-site complications at the 
expense of more frequent entry failure requiring crossover to a second entry site with 
significant heterogeneity among studies. They noted that this may have been due to an 
initial learning curve by cardiologists employing the radial technique that was followed by a 
progressive equalization in technical skills for both the radial- and femoral approaches 
through the years. (13) In our analysis nine of the twelve studies reported an initial limit of 
experience of the operators. Further two reports involved PCI centers that use radial access 
as first choice for any type of PCI. (Table 4) Unfortunately these data are too heterogeneous 
and insufficient to draw further consequences regarding the transradial operator volume 
that is indispensible for starting a transradial primary PCI program. Additionally not only the 
initial learning curve but also the constant practice is important in keeping low the 
complication rate. Furthermore we believe that maintenance of a routine elective 
transradial program alongside a continuous quality assessment is an indispensible 
background for a safe and efficacious transradial STEMI program. Transradial primary PCI 
reports dominantly originate from centers of excellence and involved trained radialists and 
this is in line with the fact that the data on access site failure showed homogeneity 
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supporting that the operators included in the studies has already completed the learning 
curve. 
In our analysis, procedural times showed significant variation among studies and TRPCI was 
not associated either with significantly longer procedural durations or with longer 
reperfusion times. This underlines the role of expertise and the notion that use of the usual 
access site in case of emergency might result in shorter procedural length. Altogether the 
heterogeneity in the different time parameters supports that other factors – most probably 
experience of the team and skills of the operator as well as the different local protocols – 
affect them more than the choice of the arterial puncture. 
The main findings of the meta-analysis of studies examining the impact of perioperative 
clopidogrel to the outcome of heart surgery are the following. Firstly, we observed a 
significant increase in mortality associated with concomitant clopidogrel therapy that was 
consistent over the studies. Secondly, clopidogrel treatment within 7 days of cardiac surgery 
increases the risk of RBC transfusions and bleeding-triggered reoperations, although, there 
was significant heterogeneity regarding this risk among studies. Thirdly, there was no 
difference regarding the rates of myocardial infarction in clopidogrel-treated patients 
undergoing cardiac operations. 
The most novel finding of this meta-analysis is the higher rate of mortality with clopidogrel 
after cardiac surgery. Although, this risk was homogenous over the individual studies, they 
were underpowered to demonstrate the excess risk, previously. The exact mechanisms are 
unknown, but the most evident explanation is a connection between bleeding-related 
complications to higher mortality. This association has been well-documented in patients 
after PCI and might be true for the surgical revascularization as well. (34; 109; 32; 110) One of the 
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included trial found that preoperative clopidogrel therapy was associated with increased risk 
of infections that might also contribute to the worse prognosis; however, based on our 
meta-analysis we can neither support nor confute this association. (101) Overall, the observed 
24% increase in the relative risk of mortality is a lot smaller than the relative risk of bleeding 
complications whilst mortality increase was not opposed by any decrease in the rate of 
postoperative MI. Furthermore, as the data is originating from observational studies we 
cannot exclude that inclusion bias of higher rate clopidogrel use or shorter delay between 
cessation and operation at higher risk patients did not influence the observed higher 
mortality. 
As expected, the meta-analysis confirmed a significant increase of bleeding-related 
complications among clopidogrel-pretreated patients. Bleeding events have been 
demonstrated to be associated with an increased risk of major adverse cardiac events 
including death and recurrent ischemic events in multiple studies. (33; 32) Though the exact 
relation between bleeding events and worse outcome is unclear, reducing bleeding seems 
equally important as recurrent ischemic events after CABG. (109) According to the subgroup 
analyses of the current study, the higher risk of bleeding-complications is not homogenous in 
every clinical situation. The risk for RBC transfusions is dropping with time between 
cessation of clopidogrel and the operation. Regarding bleeding-triggered reoperation, the 
higher risk was only evident in studies performed before 2006. Possible reasons for the 
lower reoperation rate among novel studies might include evolution in the perioperative 
care and adjunctive pharmacotherapy as well as in surgical practice. Altogether 
perioperative care and surgical practice seems to adapt to the novel circumstances when 
patients with higher bleeding risk are more frequently referred for cardiac surgery. 
Aprotinin, an antifibrinolytic serine protease inhibitor, was used for many years in elective 
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and urgent surgery, both routinely and selectively in patients with increased risk of bleeding. 
(111) Aprotinin decreased bleeding complications and reduced the need for transfusions in 
clopidogrel-treated patients undergoing CABG. (112) A recently published meta-analysis, 
which examined the efficacy of aprotinin in comparison to tranexamic acid (TXA), showed 
that aprotinin caused a more remarkable reduction in postoperative blood loss than TXA, 
and consequently fewer requirements for RBC transfusion and re-operation for bleeding. (113) 
It has also been shown that activated factor VII supplementation can decrease intractable 
bleeding in patients after cardiac surgery. (114) The fact that application of these agents may 
not only be beneficial in terms of reduction of bleeding is illustrated by a recently published 
meta-analysis proving that aprotinin increased mortality compared with TXA in cardiac 
surgery. (115) As a consequence of the increased frequency of end-organ damage aprotinin 
had been pulled from all countries and allowed only in patients without reasonable 
alternative therapy. In our subgroup analysis of studies applying aprotinin no benefit was 
demonstrable. This paradoxical relation can be explained by the observational nature of the 
included studies that may contain an inherent treatment bias linked to perioperative higher-
risk patients. 
The importance of the surgical technique on bleeding complications was well demonstrated 
in the CRUSADE registry and in the CURE trial. (35; 97) In these studies the strongest predictor 
of the RBC transfusions was the surgeon who performed the operation. There might be 
differences in bleeding complications between on-pump and off-pump operations, as well. 
Kuss et al. published a meta-analysis comparing off- and on-pump coronary artery bypass 
grafting, which has shown significantly increased RBC transfusion rates with the usage of 
cardiopulmonary bypass. (116) As off-pump CABG is getting more popular in recent years, it 
might influence the temporal changes in bleeding complications.  
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The higher mortality is exciting in the light of the introduction of novel, more potent P2Y12 
ADP-receptor antagonists. Prasugrel, that has been shown to decrease the risk of 
cardiovascular death, myocardial infarction and stroke in ACS patients after PCI, was 
associated with a 4.73-fold higher risk for major bleeding events in patients undergoing 
CABG procedures. (18) These data suggests that contrary to clopidogrel, the recommended 5-
day washout period might not be sufficient in case of prasugrel. The introduction of the 
reversible P2Y12 antagonists might change outcome of ACS patients requiring urgent bypass 
operations. According to the results of the PLATO trial, ticagrelor was not associated with 
higher risk for CABG-related bleeding complications, however, showed a significant mortality 
benefit compared to clopidogrel among patients with ACS. (117) These results promise that 
the higher mortality risk observed with irreversible ADP receptor antagonists might be 
opposed with ticagrelor in the future. 
The main finding of the meta-analysis of platelet funcition studies after coronary stent 
implantation are that patients with HPR after PCI, detected by an ADPspecific laboratory 
assay, are at a higher risk for CV death, nonfatal MI, ST, and recurrent ischemic events. 
Although there were large differences in the methodology, patient selection, and cutoff 
definition between studies, the predicted risk of CV death, MI, and ST was not 
heterogeneous. 
Before this meta-analysis, numerous observational studies have highlighted that those 
defined as clopidogrel non/low responders or with high on-treatment platelet reactivity 
were at higher risk for recurrent ischemic events. (42; 61; 65; 66; 55; 56; 57; 59; 63; 39) (69; 70; 60; 62; 64; 67; 68; 
71; 72; 58) However, it is difficult to interpret these results because of the large methodical 
heterogeneity, the diverse and often arbitrarily defined cutoffs for HPR, the lack of proven 
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compliance, and the underpowered sample sizes. The controversy of a generally accepted, 
standardized, bedside test with a consensus cutoff for selecting high-risk patients hampers 
the current recommendation for routine platelet function testing. (73) 
The findings of the current study are in line with the meta-analysis of Snoep et al published 
several years ago. (106) That analysis included 8 clinical studies that involved a total number of 
1,205 patients. Thereby, it was underpowered to detect a clear impact on separate clinical 
outcomes such as CV death or MI. Moreover, it mixed studies that reported results on the 
inhibition of platelet aggregation values, also known as clopidogrel responsiveness, with 
those measuring on-treatment platelet reactivity. Using case-control studies also decreased 
the reliability of the analysis. Since that time, a considerably higher number of articles have 
been published in the topic that enabled us to evaluate not only composite but also separate 
clinical end points among those that measured on-treatment platelet reactivity. Not only the 
number of studies but also the qualities of the studies have significantly improved during 
this period, resulting in large-scale, prospective, adequately powered single-center 
experiences. (64; 67; 71; 58) Therefore, the 3-fold higher risk for nonfatal MI, the 3.4-fold increase 
in CV death, and the 4-fold higher rate for ST were demonstrated in almost 9,200 patients. It 
is also important to notice that newer, more standardized platelet function assays (eg, 
MEAADP, VerifyNowP2Y12) have become available since the previous work of Snoep et al. To 
elucidate the differences between the available platelet function devices, the landmark 
POPULAR study performed a head-to-head comparison between 8 assays that monitored on-
treatment platelet reactivity among 1,069 patients after elective PCI. (58) As a result, LTAADP, 
the VerifyNowP2Y12 assay, and the Plateletworks device were able to discriminate between 
patients with and without death, nonfatal MI, definite ST, or ischemic stroke. (58) However, 
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the IMPACT-R, PFA collagen/ADP, and Innovance PFAP2Y assays had no predictive values 
regarding clinical outcomes. 
Although some methods such as the MEAADP and VASP assay were not tested in the study, 
these results emphasize that the available platelet function tests are not equal in detecting 
HPR or in predicting clinical outcomes. These interassays differences were suggested in prior 
studies that compared VASP phosphorylation with ADP-stimulated platelet aggregation 
measurement. According to the findings, LTAADP and MEAADP had a better predictive value 
than the completely P2Y12 specific testing.
 (63; 62; 72) Although studies using VASP 
phosphorylation were underrepresented in the current meta-analysis, our results confirmed 
its poor predictive value regarding CV death and ST. One explanation for these observations 
is that VASP measures the degree of P2Y12 receptor inhibition, but does not give a 
functionally relevant measure of aggregation as a whole; therefore, it fails to encompass the 
true extent of HPR. 
Another important lesson from the POPULAR study is that there might be substantial 
interassay differences in the predictive values according to the exact clinical outcomes. 
Whereas LTAADP 5 μmol/L had the highest OR for predicting death, LTAADP 20 μmol/L had the highest OR 
for ST; and the Plateletworks device proved to be the best to predict MI. (58) In the current 
meta-analysis, LTAADP had the highest predictive value for CV death, whereas MEAADP had 
the greatest power to predict MI and ST. These findings widen our current view on platelet 
function devices and suggest that there is not one superior device; instead, there are assays 
that best predict a separate outcome. 
In the meta-analysis, we observed large interstudy and intraassay heterogeneity in the 
prevalence of HPR that resulted in a range of 6% to 80%. This was largely driven by the 
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differences in the methodologies and in the diverse definitions of platelet reactivity cutoffs. 
Interestingly, the highest rates of HPR patients were observed in case of the most sensitive 
P2Y12 receptor saturation testing (VASP), whereas whole blood aggregometry (MEAADP) 
identified fewer patients with HPR. The higher cutoffs in platelet reactivity also resulted in 
lower prevalence rates of HPR. To evaluate whether the variability in HPR carries clinical 
consequences, the prevalence of HPR was contrasted to the predictive values regarding CV 
mortality. Those studies and devices that found an unexpectedly high prevalence rate of HPR 
(typically higher than the mean prevalence rate of 33%) did not predict mortality (Figure 
11B). It is important to emphasize that on-treatment platelet reactivity follows normal 
distribution; thereby, it is not possible to separate HPR patients on the basis of the 
laboratory assessment itself. The cutoff for HPR should be assigned on a clinically adjusted 
basis with ROC curve analysis, which might decrease the heterogeneity in the prevalence 
rate of HPR. 
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